RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology ...Middle East

YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract...

Hence then, the article about remegen to present telitacicept phase iii clinical trial results for rheumatoid arthritis patients in a late breaking abstract oral presentation session at the american college of rheumatology was published today ( Wednesday 15/11/2023 - 11:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology )

Also on site :

• With Just Two Looks, Taylor Russell Is Already In the Running for Best-Dressed at Cannes
• US Supreme Court’s uneven rulings in election lead-up causing chaos, experts say
• US extends Russian oil waiver – media